Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Stagezero Life Sciences Ltd. (SZLSF : OTC)

• Company Description    StageZero Life Sciences Ltd is dedicated to the early detection of cancer and multiple disease states through whole blood. The company's test consists of Aristotle(R), a multi-cancer panel for simultaneously screening for cancers from a single sample of blood. StageZero Life Sciences Ltd, formerly known as GeneNews Ltd., is based in TORONTO, ON. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.01 Daily Weekly Monthly 20 Day Moving Average: 15 shares Shares Outstanding: 123.55 (millions) Market Capitalization: $1.45 (millions) Beta: -0.02 52 Week High: $0.15 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -45.58% -46.54% 12 Week -59.23% -62.97% Year To Date 631.25% 552.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 70 East Beaver Creek Road Unit 30 - Richmond Hill,A6 L4B 3B2 CAN ph: 905-209-2030 fax: 905-209-2031 rgreco@stagezerols.com http://www.stagezerolifesciences.com

• General Corporate Information    Officers James R Howard-Tripp - Chief Executive Officer and Chairman Leslie Auld - Chief Financial Officer Rory Riggs - Director Harry Glorikian - Director Garth MacRae - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 852540301 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/24 Next Expected EPS Date: 09/29/25 Share - Related Items Shares Outstanding: 123.55 Most Recent Split Date: 9.00 (0.13:1) Beta: -0.02 Market Capitalization: $1.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/29/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -32.98% vs. Previous Quarter: 28.21% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©